Start Monitoring Free
Ramipril 1.25mg capsules are in shortage across the UK. SSP087 is active. Here's what patients need to know about supply, switching, and clinical alternatives.
Yes. Ramipril 1.25mg capsules are in shortage across England, Scotland, Wales and Northern Ireland. The Department of Health and Social Care (DHSC) issued Serious Shortage Protocol SSP087 on 22 April 2026, allowing community pharmacies to limit dispensing to a maximum of one month's supply per prescription — even if your prescription is normally for two or three months. No prescription charges apply when supplied under this protocol.
Ramipril 1.25mg and 2.5mg tablets, plus the oral solution, remain available but the DHSC has warned they cannot meet increased demand if all capsule patients switch to these forms. If you take 1.25mg capsules, you should contact your pharmacist about tablet alternatives now — before stocks of those run low too.
Separately, a Class 2 recall was issued on 20 April 2026 for one batch of Ramipril 10mg capsules (manufactured by Crescent Pharma) due to a packaging error — some cartons contained 5mg blister strips instead of 10mg. This is a safety issue, not a supply issue, but it adds pressure to the overall Ramipril supply chain.
Ramipril is an ACE inhibitor — one of the most commonly prescribed blood pressure medications in the UK. Over 35 million Ramipril items were dispensed in England alone during 2025, making it one of the top ten prescribed drugs in the country. It belongs to a family of medicines that all work in a similar way, but Ramipril is particularly favoured because it has a long half-life (stays in your body for a while) and can be taken once daily.
Like all ACE inhibitors, Ramipril is a prodrug — meaning the tablet or capsule you swallow is not the active medicine itself. Your liver converts it into ramiprilat, the molecule that actually does the work. This conversion is why the drug takes a little time to reach full effect (typically 2–4 weeks), and why you shouldn't expect your blood pressure to drop immediately after the first dose.
Your body has a built-in system called the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure, fluid balance, and kidney function. Here's the simplified version:
Ramipril blocks Step 3. By inhibiting ACE, it stops the production of angiotensin II. Without angiotensin II, your blood vessels relax and widen (vasodilation), and your kidneys release less aldosterone, so you lose a little more salt and water in urine. The combined effect lowers your blood pressure and reduces the workload on your heart.
ACE also breaks down a substance called bradykinin, which promotes vasodilation. By blocking ACE, Ramipril increases bradykinin levels — this gives an extra blood-pressure-lowering boost. Unfortunately, this is also why some people get a dry, tickly cough on ACE inhibitors — bradykinin irritates the airways.
The NHS and NICE guidelines recommend Ramipril for:
| Strength | Form | Typical Starting Dose | Max Daily Dose | Current Supply Status |
|---|---|---|---|---|
| 1.25mg | Capsules | 1.25mg once daily | 10mg | Shortage — SSP087 active |
| 1.25mg | Tablets | 1.25mg once daily | 10mg | Available — limited stock |
| 2.5mg | Capsules | 2.5mg once daily | 10mg | Available |
| 2.5mg | Tablets | 2.5mg once daily | 10mg | Available — demand increasing |
| 5mg | Capsules | 2.5mg → 5mg | 10mg | Available |
| 5mg | Tablets | 2.5mg → 5mg | 10mg | Available |
| 10mg | Capsules | 5mg → 10mg | 10mg | Class 2 recall — one batch |
| 10mg | Tablets | 5mg → 10mg | 10mg | Available |
You asked how medicines are crafted and what they're made of. Ramipril is a perfect example of the extraordinary chemistry that goes into a single pill. The active ingredient is not a simple molecule — it contains five chiral centres, meaning there are 32 possible stereoisomers, and only one specific 3D arrangement — the (2S,3aS,6aS)-isomer — has the pharmacological effect. Getting that exact shape is what makes the synthesis complex and expensive.
Ramipril is assembled from two complex chiral intermediates, like putting together two bespoke Lego pieces:
The first major intermediate starts from L-alanine (one of the 20 natural amino acids) and ethyl 4-phenyl-4-oxobut-2-enoate (a benzene-ring-containing compound). These undergo a stereoselective reductive amination — essentially a controlled chemical marriage where hydrogen is added in a specific direction, guided by a catalyst, so only the desired (S)-stereochemistry forms. One patent describes using catecholborane as the reducing agent with a chiral catalyst to achieve >95% selectivity for the correct isomer.
Alternative routes use hydrogenation of precursor compounds over specialised catalysts, sometimes with thiourea or urea additives to improve yield and purity. This step is critical — if the wrong stereoisomer forms here, the final Ramipril won't work properly in your body.
The (S,S,S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid core is a fused two-ring nitrogen-containing structure. In older manufacturing methods, chemists created a racemic mixture (equal parts of left- and right-handed molecules) and then had to painstakingly separate them using chiral resolution — typically with L-(+)-mandelic acid or enantioselective enzymatic hydrolysis. This is wasteful because half the material is discarded.
Modern synthesis routes aim for enantioselective construction from the start, using chiral catalysts or enzymes to build only the desired (S,S,S) form. The bicyclic core is often protected as its benzyl ester hydrochloride salt during this process — the benzyl group acts as a chemical "mask" that prevents unwanted reactions until the right moment.
This is the big moment. The alanine derivative (Building Block A) and the bicyclic core (Building Block B) are brought together in a condensation reaction to form an amide bond — the same type of bond that links amino acids in proteins. The coupling agents DCC and HOBt activate the carboxylic acid group on the bicyclic core, making it reactive enough to bond with the nitrogen on the alanine side chain.
The reaction is carried out in an organic solvent such as dichloromethane, toluene, or isopropanol, under carefully controlled temperature and pH conditions. Organic bases like triethylamine are added to neutralise acidic byproducts.
After coupling, the benzyl protecting group must be removed — this is called debenzylation. It's done by catalytic hydrogenation using palladium on charcoal (Pd/C) under hydrogen gas pressure. The palladium catalyst selectively cleaves the benzyl group without damaging the rest of the molecule.
The crude Ramipril then undergoes rigorous purification: crystallisation, washing, and chromatography to isolate the pharmacologically active (2S,3aS,6aS)-isomer and remove any impurities. Pharmaceutical-grade Ramipril must meet strict purity standards — typically >99.5% — before it can be used in tablets or capsules.
The active pharmaceutical ingredient (API) is only a tiny fraction of what you swallow. A 2.5mg Ramipril tablet contains just 2.5 milligrams of actual drug — the rest is made up of excipients (inactive ingredients) that help the tablet form, dissolve, and stay stable:
The capsule shell itself is typically gelatin — derived from collagen — with colourants to distinguish strengths. Ramipril 1.25mg capsules are often pink or red; 2.5mg may be yellow or orange; 5mg and 10mg have their own colour codes depending on the manufacturer.
| Date | Event | Impact |
|---|---|---|
| Early 2026 | Supply pressure builds on 1.25mg capsules | Pharmacies report intermittent stock-outs |
| 20 April 2026 | Class 2 recall — Crescent Pharma 10mg capsules | Packaging error: 5mg strips in 10mg cartons. Affects patient safety and supply. |
| 22 April 2026 | SSP087 issued by DHSC | Pharmacies can limit 1.25mg capsule supply to 1 month. Applies UK-wide. |
| 22 April 2026 | MSN/2026/022 published | Official notification to all pharmacies and GPs. |
| 29 May 2026 | SSP087 expires (unless extended) | If supply not restored, expect SSP extension or new protocol. |
| Late 2026 | Potential broader supply pressure | Iran conflict / Strait of Hormuz blockade may affect raw ingredient supply. |
The exact cause of the 1.25mg capsule shortage has not been fully disclosed by the DHSC, but several factors are known to contribute to ACE inhibitor supply disruptions in general:
Not every Ramipril patient is impacted equally:
The good news is that Ramipril is not unique. There are several medicines in the same class (ACE inhibitors) and a related class (ARBs) that work in a very similar way. Your GP will choose the best alternative based on your specific condition, other medications, kidney function, and any side effects you've had.
Lisinopril is the UK's most prescribed ACE inhibitor and the closest clinical equivalent to Ramipril. It works by the exact same mechanism (ACE inhibition) and is approved for all the same conditions — hypertension, heart failure, post-MI, and kidney protection.
Dose equivalence: The commonly cited equivalence is that Lisinopril 10mg ≈ Ramipril 2.5mg. However, these are approximate — your GP will typically start you on the standard starting dose of the new drug and titrate up based on your blood pressure response.
How the switch works: Stop Ramipril and start Lisinopril the next day. No washout period is needed. Your GP should check your blood pressure and arrange a blood test for kidney function and potassium within 1–2 weeks.
Side effect profile: Very similar to Ramipril — dry cough, dizziness, hyperkalaemia. The cough incidence is roughly the same (~10–15% of patients). If you already get a cough on Ramipril, you'll likely get it on Lisinopril too.
Availability: Lisinopril has multiple UK manufacturers and is generally well-stocked. However, increased demand from Ramipril switchers may put pressure on supply in some areas.
Perindopril is another ACE inhibitor with a long half-life, taken once daily like Ramipril. It comes in two salt forms: perindopril arginine (the newer form, better absorption) and perindopril erbumine (the older form).
Dose equivalence: Perindopril 4mg ≈ Ramipril 5mg (approximate). For lower Ramipril doses, Perindopril 2mg is roughly equivalent to Ramipril 1.25–2.5mg.
Key advantage: Perindopril has excellent long-term outcome data — the PROGRESS trial showed significant stroke reduction, and the EUROPA trial demonstrated cardiovascular protection in stable coronary artery disease.
Side effect profile: Similar to Ramipril. Slightly lower incidence of cough in some studies, but not dramatically different.
Enalapril is an older ACE inhibitor, often taken twice daily rather than once daily because it has a shorter half-life than Ramipril. This can be a disadvantage for adherence — forgetting a dose matters more.
Dose equivalence: Enalapril 5mg ≈ Ramipril 2.5mg; Enalapril 20mg ≈ Ramipril 5mg (approximate).
When it's suitable: Enalapril is a good option if once-daily alternatives are also in short supply. It's widely available and inexpensive. However, if adherence is a concern for you (e.g. if you often forget doses), a once-daily option like lisinopril or perindopril may be preferred.
If you had side effects on Ramipril — especially the dry cough or angioedema — your GP may switch you to an angiotensin receptor blocker (ARB) instead of another ACE inhibitor. ARBs block the action of angiotensin II at the receptor level (step 4 in the RAAS pathway) rather than stopping its production (step 3).
Key advantage: ARBs do not increase bradykinin, so the dry cough incidence is dramatically lower (~2–3% vs 10–15%). This makes ARBs much more tolerable for cough-sensitive patients.
Dose equivalence: There is no exact conversion, but Losartan 50mg is broadly equivalent in blood-pressure-lowering effect to Ramipril 5mg or Lisinopril 10mg.
NICE guidance: If an ACE inhibitor is not tolerated due to cough, NICE recommends offering an ARB as an alternative. Losartan is the most commonly prescribed ARB in the UK.
Candesartan is another ARB with the added advantage of being specifically approved for heart failure with reduced ejection fraction (HFrEF) in patients who cannot tolerate ACE inhibitors. It has strong evidence from the CHARM programme.
Dose equivalence: Candesartan 4–8mg ≈ Ramipril 2.5mg (approximate). Typical maintenance dose is 8–32mg daily.
When it's the best choice: If you have heart failure and cannot take ACE inhibitors, candesartan is often the preferred ARB. It also has a very flat dose-response curve, meaning blood pressure reduction is consistent across doses.
| Medicine | Low Dose | Medium Dose | High Dose | Frequency |
|---|---|---|---|---|
| Ramipril | 1.25–2.5mg | 5mg | 10mg | Once daily |
| Lisinopril | 5mg | 10–20mg | 40mg | Once daily |
| Perindopril | 2mg | 4mg | 8mg | Once daily |
| Enalapril | 2.5–5mg | 10–20mg | 40mg | Once or twice daily |
| Losartan (ARB) | 25mg | 50mg | 100mg | Once daily |
| Candesartan (ARB) | 4mg | 8–16mg | 32mg | Once daily |
Based on the current DHSC guidance, the shortage of Ramipril 1.25mg capsules is expected to continue until at least 29 May 2026 — the expiry date of SSP087. However, supply disruptions often extend beyond initial estimates, especially when the root cause is manufacturing capacity rather than a temporary logistics issue.
Several factors could extend the shortage:
MediWatch will update this page immediately when the DHSC issues new notifications, extends SSP087, or confirms that normal supply has resumed. Sign up for alerts below to be notified the moment the shortage ends.
Ramipril has faced supply disruptions before — this is not an isolated incident:
The pattern suggests that low-strength Ramipril (1.25mg and 2.5mg) is more vulnerable to shortage than higher strengths. This makes clinical sense — 1.25mg and 2.5mg are the starting doses for elderly patients, post-MI patients, and those with kidney impairment. These patient groups cannot safely start on higher doses, so when low-strength supply fails, there is no clinical workaround within the same drug.
A Serious Shortage Protocol (SSP) is an emergency measure that the DHSC can activate when a medicine is in critical shortage. It temporarily changes the normal rules around dispensing so that patients can still get treatment.
Under a normal prescription, a pharmacist must supply exactly what the GP wrote — same medicine, same strength, same form. Under an SSP, they have limited flexibility:
For Ramipril, SSP087 allows pharmacists to limit 1.25mg capsule supply to one month and to supply without a prescription charge when the SSP is invoked. It does NOT currently allow pharmacists to substitute a different medicine (like lisinopril) without a new prescription — you still need your GP for that.
SSPs are time-limited and are reviewed regularly. SSP087 expires on 29 May 2026 unless the DHSC extends it.
Yes — Ramipril 1.25mg capsules are in shortage across the UK. The DHSC issued SSP087 on 22 April 2026. Intermittent supply issues are expected until at least 29 May 2026. Ramipril 1.25mg and 2.5mg tablets remain available but cannot meet increased demand if all capsule patients switch.
Ramipril is an ACE inhibitor used to treat high blood pressure, heart failure, kidney disease (including diabetic nephropathy), and to prevent heart attacks and strokes in high-risk patients. It works by blocking the angiotensin-converting enzyme (ACE), which relaxes blood vessels and reduces blood pressure.
Do not stop taking Ramipril suddenly. First, ask your pharmacist if 1.25mg or 2.5mg tablets are available instead of capsules — this is the simplest switch. If no Ramipril is available, contact your GP to discuss switching to an alternative ACE inhibitor (lisinopril, perindopril) or an ARB (losartan, candesartan). Your GP will choose the safest option based on your medical history.
The main alternatives are other ACE inhibitors — lisinopril (most common), perindopril, and enalapril — or ARBs like losartan and candesartan. Lisinopril 10mg is approximately equivalent to Ramipril 2.5mg. If you had side effects (dry cough, angioedema) on Ramipril, an ARB is usually better tolerated. Always consult your GP before switching.
The DHSC expects intermittent supply issues until at least 29 May 2026, when SSP087 expires. However, manufacturing recovery can take longer than initially estimated. MediWatch will update this page immediately when the DHSC confirms resolution or extends the protocol.
Yes — Ramipril 1.25mg and 2.5mg tablets are available and contain the exact same active ingredient as the capsules. Your pharmacist can supply these under normal dispensing rules. If your prescription specifies capsules, your pharmacist may need to confirm the switch with your GP, but this is usually straightforward.
No — SSP087 for Ramipril allows quantity limits and form substitution (capsules → tablets) but does not allow substitution with a different medicine (e.g. lisinopril) without a new prescription. If you need to switch to a different drug, your GP must issue a new prescription.
Yes — SSP087 applies UK-wide. The shortage affects all four nations because the same manufacturers supply the entire UK market. However, local stock levels vary — a pharmacy in Glasgow may have tablets when a pharmacy in Cardiff does not. It is worth calling multiple pharmacies in your area.
No — under SSP087, there are no prescription charges when Ramipril 1.25mg capsules are supplied under the protocol, even if you normally pay for prescriptions. This applies in England, Scotland, Wales and Northern Ireland.
The dry cough is caused by increased bradykinin levels — a side effect of all ACE inhibitors. It affects about 10–15% of patients. If you switch to another ACE inhibitor (lisinopril, perindopril, enalapril), the cough will likely continue. If you switch to an ARB (losartan, candesartan), the cough risk drops to ~2–3% because ARBs don't increase bradykinin. Talk to your GP if the cough is bothering you.
MediWatch monitors DHSC and NHS notifications every 2 hours. Sign up for free alerts and we'll notify you the moment the Ramipril shortage is resolved.
Set Up AlertThis article was last reviewed on 6 May 2026 against the following official sources:
MediWatch sources all shortage data from official NHS England and DHSC notifications. We do not provide medical advice — always consult your GP or pharmacist before changing medication.
